

Christian Arsov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/538332/publications.pdf>

Version: 2024-02-01

46
papers

1,283
citations

394421

19
h-index

361022

35
g-index

49
all docs

49
docs citations

49
times ranked

1700
citing authors

#	ARTICLE	IF	CITATIONS
1	MRI grading for the prediction of prostate cancer aggressiveness. <i>European Radiology</i> , 2022, 32, 2351-2359.	4.5	20
2	Comparison of 3T mpMRI and pelvic CT examinations for detection of lymph node metastases in patients with prostate cancer. <i>European Journal of Radiology</i> , 2022, 147, 110110.	2.6	6
3	Value of T ₂ Mapping MRI for Prostate Cancer Detection and Classification. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 413-422.	3.4	8
4	A randomized trial of risk-adapted screening for prostate cancer in young men—Results of the first screening round of the PROBASE trial. <i>International Journal of Cancer</i> , 2022, 150, 1861-1869.	5.1	23
5	Is there a diagnostic benefit of late-phase abdomino-pelvic PET/CT after urination as part of whole-body ⁶⁸ Ga-PSMA-11 PET/CT for restaging patients with biochemical recurrence of prostate cancer after radical prostatectomy?. <i>EJNMMI Research</i> , 2022, 12, 12.	2.5	8
6	Arterial input function for quantitative dynamic contrast-enhanced MRI to diagnose prostate cancer. <i>European Journal of Radiology</i> , 2022, 28, 108-114.		2
7	Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate. <i>Scientific Reports</i> , 2022, 12, 6746.	3.3	4
8	Pre-operative magnetic resonance imaging can predict prostate cancer with risk for positive surgical margins. <i>Abdominal Radiology</i> , 2022, 47, 2486-2493.	2.1	10
9	PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications. <i>European Journal of Radiology</i> , 2021, 136, 109556.	2.6	17
10	Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection. <i>PLoS ONE</i> , 2021, 16, e0249532.	2.5	9
11	Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion-guided biopsy. <i>European Journal of Radiology</i> , 2021, 137, 109587.	2.6	9
12	Arterial spin labelling as a gadolinium-free alternative in the detection of prostate cancer. <i>Magnetic Resonance Imaging</i> , 2021, 80, 33-38.	1.8	5
13	Comparison and prediction of artefact severity due to total hip replacement in 1.5T versus 3T MRI of the prostate. <i>European Journal of Radiology</i> , 2021, 144, 109949.	2.6	12
14	Magnetic resonance imaging improves the prediction of tumor staging in localized prostate cancer. <i>Abdominal Radiology</i> , 2021, 46, 2751-2759.	2.1	13
15	Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020, 192, 441-447.	1.3	19
16	Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies. <i>Journal of Personalized Medicine</i> , 2020, 10, 270.	2.5	7
17	Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study. <i>European Radiology</i> , 2020, 30, 6042-6051.	4.5	20
18	Advanced diffusion weighted imaging of the prostate: Comparison of readout-segmented multi-shot, parallel-transmit and single-shot echo-planar imaging. <i>European Journal of Radiology</i> , 2020, 130, 109161.	2.6	29

#	ARTICLE	IF	CITATIONS
19	Can you trust the Prostate Imaging Reporting and Data System (PI-RADS) in special cases?. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 192, 580-583.	1.3	0
20	Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer. Journal of Urology, 2020, 204, 1242-1248.	0.4	14
21	Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. European Urology, 2019, 75, 310-318.	1.9	129
22	Comparison of analgesic techniques in MRI-guided in-bore prostate biopsy. European Radiology, 2019, 29, 6965-6970.	4.5	3
23	Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients. European Journal of Radiology, 2019, 113, 1-6.	2.6	11
24	Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse. World Journal of Urology, 2019, 37, 2081-2090.	2.2	5
25	Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate. Journal of Urology, 2018, 199, 691-698.	0.4	38
26	Current Utilization and Acceptance of Multiparametric MRI in the Diagnosis of Prostate Cancer. A Regional Survey. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2018, 190, 419-426.	1.3	6
27	Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate. European Radiology, 2018, 28, 17-23.	4.5	34
28	Influence of arterial input function (AIF) on quantitative prostate dynamic contrast-enhanced (DCE) MRI and zonal prostate anatomy. Magnetic Resonance Imaging, 2018, 53, 28-33.	1.8	12
29	Magnetic resonance imaging of the prostate at 1.5 versus 3.0 T: A prospective comparison study of image quality. European Journal of Radiology, 2017, 90, 192-197.	2.6	80
30	Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. Molecular Oncology, 2016, 10, 825-837.	4.6	20
31	Targeted MRI-guided prostate biopsy: are two biopsy cores per MRI-lesion required?. European Radiology, 2016, 26, 3858-3864.	4.5	21
32	MRI-Guided In-Bore Biopsy: Differences Between Prostate Cancer Detection and Localization in Primary and Secondary Biopsy Settings. American Journal of Roentgenology, 2016, 206, 92-99.	2.2	54
33	Comparison of patient comfort between MR-guided in-bore and MRI/ultrasound fusion-guided prostate biopsies within a prospective randomized trial. World Journal of Urology, 2016, 34, 215-220.	2.2	23
34	The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2061-2068.	2.5	48
35	Prospective Randomized Trial Comparing Magnetic Resonance Imaging (MRI)-guided In-bore Biopsy to MRI-ultrasound Fusion and Transrectal Ultrasound-guided Prostate Biopsy in Patients with Prior Negative Biopsies. European Urology, 2015, 68, 713-720.	1.9	155
36	Feasibility of diffusional kurtosis tensor imaging in prostate MRI for the assessment of prostate cancer: Preliminary results. Magnetic Resonance Imaging, 2014, 32, 880-885.	1.8	52

#	ARTICLE	IF	CITATIONS
37	Increased signal intensity of prostate lesions on high b-value diffusion-weighted images as a predictive sign of malignancy. <i>European Radiology</i> , 2014, 24, 209-213.	4.5	19
38	Predictive power of the ESUR scoring system for prostate cancer diagnosis verified with targeted MR-guided in-bore biopsy. <i>European Journal of Radiology</i> , 2014, 83, 2103-2108.	2.6	37
39	MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. <i>European Radiology</i> , 2014, 24, 2582-2589.	4.5	78
40	Prospective Evaluation of Magnetic Resonance Imaging Guided In-bore Prostate Biopsy versus Systematic Transrectal Ultrasound Guided Prostate Biopsy in Biopsy Naïve Men with Elevated Prostate Specific Antigen. <i>Journal of Urology</i> , 2014, 192, 1374-1379.	0.4	98
41	Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy—a pilot study. <i>Anticancer Research</i> , 2014, 34, 2459-66.	1.1	8
42	Holmium laser ablation of the prostate (HoLAP): intermediate-term results of 144 patients. <i>World Journal of Urology</i> , 2013, 31, 1253-1259.	2.2	11
43	Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 622-627.	1.6	39
44	Prospective Randomized Evaluation of Risk-adapted Prostate-specific Antigen Screening in Young Men: The PROBASE Trial. <i>European Urology</i> , 2013, 64, 873-875.	1.9	43
45	Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 762-771.	1.6	6
46	Repeat transrectal ultrasound biopsies with additional targeted cores according to results of functional prostate MRI detects high-risk prostate cancer in patients with previous negative biopsy and increased PSA - a pilot study. <i>Anticancer Research</i> , 2012, 32, 1087-92.	1.1	16